Aquinas Taps Pharma Veteran Ryan Bleeks to Drive Next-Gen Training Growth

DUBLIN, Ohio – July 01, 2026 – OneCompass Holdings has appointed Ryan Bleeks, a seasoned pharmaceutical executive with a deep history in product commercialization, as the new President of Aquinas Leadership Group. While leadership changes are common, this move represents a calculated strategic pivot, signaling a deliberate effort by OneCompass to infuse its specialized training subsidiary with the high-stakes perspective of a frontline industry operator. The appointment comes just over a year after OneCompass, a diversified ESOP holding company, acquired Aquinas, and it aims to accelerate the training firm’s growth in a rapidly evolving life sciences market.

Bleeks is tasked with building on the foundation established by outgoing President Jamie Giannantonio, who will remain with the company in a key operational role. This transition is more than a simple handover; it’s a strategic realignment designed to bridge the gap between corporate training and the commercial realities of launching multi-million-dollar therapies. For an industry grappling with AI integration, personalized medicine, and immense regulatory pressure, the message is clear: the future of training lies in understanding the business from the inside out.

A New Growth Engine: Bleeks’ Commercialization Expertise

Ryan Bleeks is not a traditional training and development executive. His 20-year career has been forged in the crucible of pharmaceutical sales and C-suite leadership, primarily within the highly competitive ophthalmology and optometry sectors. His track record includes the launch of more than a dozen products, a critical experience that provides him with an intimate understanding of what sales teams and medical affairs professionals truly need to succeed.

Before joining Aquinas, Bleeks served as CEO of Visiox Pharmaceuticals, where he was instrumental in navigating the company through complex strategic maneuvers, including the acquisition of the U.S. license for Omlonti® and a definitive merger agreement with Ocuvex Therapeutics in 2024. His leadership experience also includes senior roles at RVL Pharmaceuticals, where he managed the launch of UPNEEQ®, and at Sun Pharma, where he directed the successful commercial rollouts of CEQUA™ and XELPROS™. This background in executing high-pressure product launches and strategic transactions gives him a unique vantage point on the core challenges facing Aquinas’s clientele.

"I am honored to lead Aquinas Leadership Group and advance the foundation that Jamie and the team have built," Bleeks stated. "I look forward to leveraging my experience leading organizations through major growth and value inflection points to accelerate the business, execute with discipline, and broaden the company's strategic potential." His appointment suggests a shift in focus for Aquinas, moving beyond conventional training methodologies toward creating programs that are directly tied to commercial outcomes, market access, and competitive positioning.

Building on a Strong Foundation: The Giannantonio Legacy

This new chapter for Aquinas is being built upon a solid legacy of leadership and stability. Jamie Giannantonio, who led the organization for 12 years, is credited with successfully navigating its transition from a founder-led business to a key asset within the OneCompass portfolio following its acquisition in early 2025. Her deep institutional knowledge and operational expertise are not being lost in the transition. Research confirms Giannantonio continues to serve as the company's Chief Operating Officer, a role that ensures a seamless integration of Bleeks' strategic vision with Aquinas's established operational strengths.

Matt Hartman, Chairman and CEO of OneCompass Holdings, emphasized the importance of this continuity. "Since acquiring Aquinas in early 2025, Jamie has done an excellent job of managing the business through the transition... Jamie's continued support of Ryan as we transition the leadership of the business will be critical to the long-term success of Aquinas," he said. This structured approach to leadership evolution, which retains a veteran operator while bringing in a new strategic leader, mitigates risk and positions the company for accelerated, yet stable, growth.

Giannantonio herself endorsed the move, reflecting a culture focused on forward momentum. "I have always believed in the phrase, 'Onward and Upward,' and I can confidently say that is exactly where Aquinas is headed," she commented. "Ryan is the right leader to guide the organization into its next chapter." Her continued presence as COO ensures that the deep client relationships and operational excellence cultivated over the past decade will anchor the company as it embraces a more aggressive growth strategy.

The OneCompass Playbook: An ESOP Model Fueling Diversification

The strategic thinking behind Bleeks’ appointment is deeply rooted in the unique corporate structure of its parent company. OneCompass Holdings is not a typical private equity firm; it is a 100% employee-owned ESOP holding company. This model eschews short-term exit strategies in favor of long-term, sustainable value creation for its employee-owners. Its portfolio, historically centered on logistics and transportation with companies like FST Logistics and Hyway Transportation, has been strategically diversified with the acquisition of Aquinas.

Aquinas is not just another portfolio company; it represents a core component of OneCompass’s overarching operational philosophy, the "Pillars of Excellence." As a learning and development firm, Aquinas directly embodies the "education" pillar, providing the infrastructure to upskill and develop talent across the entire OneCompass ecosystem. This creates a powerful synergy where Aquinas can both grow as a standalone business and serve as an internal engine for strengthening the human capital of its sister companies. The ESOP model fosters a culture of shared ownership and long-term commitment, providing a stable platform for a company like Aquinas to invest in innovation without the pressures of a looming sale.

Navigating the Future of Pharma Training

The pharmaceutical industry is at an inflection point. The rise of personalized medicine, the integration of AI in drug discovery, and the use of VR and AR for complex procedural training are no longer theoretical concepts but active drivers of change. This technological and scientific evolution demands a more sophisticated and agile approach to workforce training. Sales and medical teams must be equipped to discuss complex genomics, data-driven therapies, and novel digital health solutions.

This is the landscape that Ryan Bleeks and Aquinas are now tasked with navigating. Bleeks’ experience in the ophthalmology space—a field known for its rapid technological innovation—positions him well to understand the need for cutting-edge training solutions. The challenge for Aquinas will be to translate its expertise in custom learning into programs that can keep pace with an industry where the goalposts are constantly moving. Under new leadership, the firm is poised to develop training that doesn't just inform but empowers pharmaceutical professionals to compete and win in a new era of medicine.